| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3285984 | Clinical Gastroenterology and Hepatology | 2006 | 4 Pages |
Abstract
Background & Aims: Ezetimibe was introduced recently as a new class of cholesterol-lowering drugs. Until now only limited increases of transaminase levels were reported. Methods: We studied 2 patients with severe hepatic side effects of ezetimibe in a general community hospital. Results: Ezetimibe may lead to 2 distinct types of severe hepatic side effects. Conclusions: Ezetimibe may rarely cause hepatotoxicity, severe cholestatic hepatitis, or acute autoimmune hepatitis.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Mark F.J. Stolk, Marco C.J.M. Becx, Karel C. Kuypers, Cees A. Seldenrijk,